Table 1 Demographical data and number of analysed metastases for each patient enrolled in the study
From: Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases
Patient | Age at CT (years) | Sex | Primary cancer site | Number of analysed metastases | Lines of treatment | Chemotherapy regimens |
|---|---|---|---|---|---|---|
1 | 77 | F | Rectum | 1 | 2 | FOLFOX + bevacizumab FOLFIRI + cetuximab |
2 | 66 | M | Colon (left) | 5 | 2 | FOLFOX FOLFIRI + cetuximab |
3 | 62 | M | Colon (left) | 3 | 4 | FOLFIRI + cetuximab Regorafenib Trifluridine/tipiracil Capecitabine |
4 | 59 | M | Colon (left) | 1 | 2 | FOLFOX FOLFIRI + cetuximab |
5 | 56 | M | Rectum | 1 | 2 | FOLFIRI + cetuximab Not available |
6 | 40 | M | Colon (left) | 2 | 2 | FOLFOX + panitumumab FOLFIR I + bevacizumab |
7 | 61 | M | Colon (left) | 4 | 2 | FOLFOX + panitumumab FOLFIRI + aflibercept |
8 | 56 | M | Colon (right) | 6 | 2 | FOLFOX + panitumumab FOLFIRI + aflibercept |
9 | 47 | M | Colon (left) | 5 | 2 | FOLFOX + cetuximab FOLFIRI + bevacizumab |
10 | 32 | M | Colon (left) | 7 | 3 | FOLFOXIRI + bevacizumab FOLFIRI + aflibercept Panitumumab |
11 | 66 | M | Colon (left) | 6 | 2 | XELIRI FOLFOX + bevacizumab |
12 | 63 | F | Colon (left) | 8 | 2 | FOLFOX + panitumumab FOLFIRI + bevacizumab |
13 | 61 | F | Colon (left) | 1 | 2 | XELOX + bevacizumab FOLFIRI + cetuximab |
14 | 52 | M | Rectum | 2 | 2 | FOLFOX FOLFOX + bevacizumab |
15 | 41 | M | Colon (left) | 5 | 1 | FOLFOX + panitumumab |
16 | 59 | M | Rectum | 4 | 1 | FOLFIRI + bevacizumab |
17 | 60 | M | Colon (left) | 9 | 3 | FOLFOX + cetuximab FOLFIRI + bevacizumab FOLFIRI |